Deep Learning Diagnostic and Risk-stratification for IPF and COPD

RecruitingOBSERVATIONAL
Enrollment

160

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

October 6, 2024

Study Completion Date

October 31, 2024

Conditions
Lung; Disease, Interstitial, With FibrosisPulmonary Disease, Chronic ObstructiveArtificial Intelligence
Interventions
DEVICE

Lung auscultation

Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).

DEVICE

Lung ultrasound

Lung ultrasonography

OTHER

Quality of Life's questionnaires

Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)

DIAGNOSTIC_TEST

Pulmonary functional tests

Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.

Trial Locations (1)

1951

RECRUITING

Centre Hospitalier du Valais Romand, Sion

All Listed Sponsors
collaborator

University Hospital, Geneva

OTHER

collaborator

Swiss Federal Institute of Technology

OTHER

collaborator

Hôpital du Valais

OTHER

lead

Pediatric Clinical Research Platform

OTHER

NCT05318599 - Deep Learning Diagnostic and Risk-stratification for IPF and COPD | Biotech Hunter | Biotech Hunter